Retrospective Study of AlloMend Acellular Dermal Matrix (ADM) Allograft and Pre-Pectoral Breast Reconstruction

Running, not enrolling

Conditions studied: Pre-Pectoral Breast Reconstruction Following Mastectomy

In brief

This retrospective, single-site study will provide information regarding the efficiency of AlloMend® Acellular Dermal Matrix allograft in Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Key facts

Study ID

NCT06853964

Run by

AlloSource

People needed

100

Starts

2025-01-27

Expected to finish

2026-05-31

Last updated by the study team

2025-11-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet the following inclusion criteria to participate in this study:
• Female ≥ 18 years old.
• Patients have undergone a single or double mastectomy, followed by AlloMend® Acellular Dermal Matrix -assisted, pre-pectoral breast reconstruction.
• Patients have undergone either one-stage (direct-to-implant) or two-stage (expander-to-implant), unilateral or bilateral pre-pectoral breast reconstruction using AlloMend®.

You may not qualify if…

• Patients must not meet any of the following criteria to be considered for this clinical trial:
• Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
• Did not have post-operative evaluations at the clinical site.

Where it is running

• Janiga MDs Plastic Surgery and Cosmetic Center — Reno, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.